Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712200 · ClinicalTrials.gov registry record · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A Phase 3 study of Atrial Fibrillation (AF), sponsored by Anthos Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,900
- Enrollment target
- 20
- Study locations
NCT05712200: Recruiting Phase 3 study of Atrial Fibrillation (AF), sponsored by Anthos Therapeutics.
NCT05712200 is a Phase 3 study of Atrial Fibrillation (AF) that is actively recruiting participants, run by Anthos Therapeutics. The registered enrollment target is 1,900 participants, above the 608-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (213% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05712200, a Phase 3 study of Atrial Fibrillation (AF), is actively recruiting participants, sponsored by Anthos Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,900 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Primary Outcome
Undetermined strokes will be counted as ischemic strokes
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Abelacimab
Study Locations (20)
California
- Anthos Investigative Site 9929 - Huntington Beach
- Anthos Investigative Site 9959 - Imperial
- Anthos Investigative Site 9921 - Lancaster
- Anthos Investigative Site 1078 - Loma Linda
- Anthos Investigative Site 1077 - Los Angeles
- Anthos Investigative Site 1015 - Northridge
- Anthos Investigative Site 1070 - Redding
- Anthos Investigative Site 1071 - San Dimas
- Anthos Investigative Site 1076 - Santa Ana
- Anthos Investigative Site 9938 - Santa Rosa
- Anthos Investigative Site 9908 - South Gate
- Anthos Investigative Site 9907 - Vista
Alabama
- Anthos Investigative Site 1040 - Birmingham
- Anthos Investigational site 9939 - Birmingham
- Anthos Investigative Site 9947 - Birmingham
- Anthos Investigative Site 1041 - Mobile
Arizona
- Anthos Investigative Site 1089 - Gilbert
- Anthos Investigative Site 1099 - Peoria
- Anthos Investigative Site 9906 - Phoenix
- Anthos Investigative Site 9927 - Yuma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2022-12-27 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
What NCT05712200 shows while recruiting
NCT05712200 is an interventional study that assigns participants to a tested intervention. Its 1,900 participants enrollment target places it among the larger protocols in the corpus, above the 608-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (213% higher).
The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05712200 names 20 study sites across 3 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05712200 about?
NCT05712200 is a clinical study titled "Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)". A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
What is the current status of trial NCT05712200?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,900 participants. The study started on 2022-12-27. Estimated completion is 2026-10-31.
What conditions does trial NCT05712200 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF).
What interventions are being tested in trial NCT05712200?
The interventions under investigation include: Placebo (DRUG), Abelacimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05712200?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05712200 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05712200's enrollment target sits among peer trials
1,900 1st of 17 higher than 17 of 17 other Atrial Fibrillation (AF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation (AF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
RECRUITING · NA
-
Incidence of Long-TeRm Atrial Fibrillation After Acute Illness
RECRUITING
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
RECRUITING
-
Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
RECRUITING
-
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
- NCT07280065 · 1,900 participants · Phase 3
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI